These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30464532)

  • 1. EZH2 contributes to 5-FU resistance in gastric cancer by epigenetically suppressing FBXO32 expression.
    Wang C; Li X; Zhang J; Ge Z; Chen H; Hu J
    Onco Targets Ther; 2018; 11():7853-7864. PubMed ID: 30464532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2 Contributes To Cisplatin Resistance In Breast Cancer By Epigenetically Suppressing miR-381 Expression.
    Dou D; Ge X; Wang X; Xu X; Zhang Z; Seng J; Cao Z; Gu Y; Han M
    Onco Targets Ther; 2019; 12():9627-9637. PubMed ID: 32009798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TUG1 confers cisplatin resistance in esophageal squamous cell carcinoma by epigenetically suppressing PDCD4 expression via EZH2.
    Xu C; Guo Y; Liu H; Chen G; Yan Y; Liu T
    Cell Biosci; 2018; 8():61. PubMed ID: 30519392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TUG1 confers Adriamycin resistance in acute myeloid leukemia by epigenetically suppressing miR-34a expression via EZH2.
    Li Q; Song W; Wang J
    Biomed Pharmacother; 2019 Jan; 109():1793-1801. PubMed ID: 30551433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCAT-1 contributes to cisplatin resistance in gastric cancer through epigenetically silencing PTEN via recruiting EZH2.
    Li H; Ma X; Yang D; Suo Z; Dai R; Liu C
    J Cell Biochem; 2020 Feb; 121(2):1353-1361. PubMed ID: 31478258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EZH2 Contributes to 5-FU Resistance in Gastric Cancer by Epigenetically Suppressing FBXO32 Expression [Retraction].
    Onco Targets Ther; 2023; 16():673-674. PubMed ID: 37551312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knockdown of PLA2G2A sensitizes gastric cancer cells to 5-FU in vitro.
    Chen D; Jiao XL; Liu ZK; Zhang MS; Niu M
    Eur Rev Med Pharmacol Sci; 2013 Jul; 17(13):1703-8. PubMed ID: 23852891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MeCP2 confers 5-fluorouracil resistance in gastric cancer via upregulating the NOX4/PKM2 pathway.
    Qin Y; Ma X; Guo C; Cai S; Ma H; Zhao L
    Cancer Cell Int; 2022 Feb; 22(1):86. PubMed ID: 35180871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HOXA13, Negatively Regulated by miR-139-5p, Decreases the Sensitivity of Gastric Cancer to 5-Fluorouracil Possibly by Targeting ABCC4.
    Chen Z; Qin Z; Li L; Wo Q; Chen X
    Front Oncol; 2021; 11():645979. PubMed ID: 34094932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long noncoding RNA SNHG6 silencing sensitized esophageal cancer cells to 5-FU via EZH2/STAT pathway.
    Tan R; Liu J; Wang J; Zhang W; He M; Zhang Y
    Sci Rep; 2023 Apr; 13(1):5363. PubMed ID: 37005451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA UCA1 promotes cisplatin resistance in gastric cancer via recruiting EZH2 and activating PI3K/AKT pathway.
    Dai Q; Zhang T; Pan J; Li C
    J Cancer; 2020; 11(13):3882-3892. PubMed ID: 32328192
    [No Abstract]   [Full Text] [Related]  

  • 12. Silenced PITX1 promotes chemotherapeutic resistance to 5-fluorocytosine and cisplatin in gastric cancer cells.
    Shen X; Gu Y; Yu S; Gong P; Mao Y; Li Y; Zheng Y; Qiao F; Zhao Z; Fan H
    Exp Ther Med; 2019 May; 17(5):4046-4054. PubMed ID: 31007741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitization of Gastric Cancer Cells to 5-FU by MicroRNA-204 Through Targeting the TGFBR2-Mediated Epithelial to Mesenchymal Transition.
    Li LQ; Pan D; Chen Q; Zhang SW; Xie DY; Zheng XL; Chen H
    Cell Physiol Biochem; 2018; 47(4):1533-1545. PubMed ID: 29940566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-195 reverses 5-FU resistance through targeting HMGA1 in gastric cancer cells.
    Wang CQ
    Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3771-3778. PubMed ID: 31115003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA GAS5 facilitates nasopharyngeal carcinoma progression through epigenetically silencing PTEN
    Zhao D; Li Y; Yu M
    RSC Adv; 2019 Oct; 9(54):31691-31698. PubMed ID: 35527982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancer of zeste homolog 2 exerts functions in gastric cancer development via modulating microRNA-222-3p methylation and WEE1 expression.
    Feng Y; Wang C; Shi T; Liu W; Liu H; Zhu B; Gao F
    Chem Biol Drug Des; 2022 Sep; 100(3):320-333. PubMed ID: 35765903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silencing the EZH2 gene by RNA interference reverses the drug resistance of human hepatic multidrug-resistant cancer cells to 5-Fu.
    Zhang Y; Liu G; Lin C; Liao G; Tang B
    Life Sci; 2013 May; 92(17-19):896-902. PubMed ID: 23562851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TWEAK/Fn14 signaling mediates gastric cancer cell resistance to 5-fluorouracil via NF-κB activation.
    Kwon OH; Kim JH; Kim SY; Kim YS
    Int J Oncol; 2014 Feb; 44(2):583-90. PubMed ID: 24337061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer.
    Pan YM; Wang CG; Zhu M; Xing R; Cui JT; Li WM; Yu DD; Wang SB; Zhu W; Ye YJ; Wu Y; Wang S; Lu YY
    Mol Cancer; 2016 Dec; 15(1):79. PubMed ID: 27938379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking lncRNA-SNHG16 sensitizes gastric cancer cells to 5-Fu through targeting the miR-506-3p-PTBP1-mediated glucose metabolism.
    Ding Y; Gao S; Zheng J; Chen X
    Cancer Metab; 2022 Nov; 10(1):20. PubMed ID: 36447254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.